Drug
Toripalimab (JS001 )
Toripalimab (JS001 ) is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(1)
Other(1)
Detailed Status
unknown1
Terminated1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
unknown133%
terminated133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
NCT06823427
terminatedphase_1
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
NCT03867370
unknownphase_1
A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma
NCT05751486
Clinical Trials (3)
Showing 3 of 3 trials
NCT06823427Phase 2
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
NCT03867370Phase 1
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
NCT05751486Phase 1
A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3